How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

In a plenary session at the annual American Academy of Neurology meeting, Paul Edison, MD, PhD, of Imperial College London in ...

Five scientists won this year’s Breakthrough Prize in Life Sciences for their work on GLP-1 and the development of drugs for ...

Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key ...

In April 2024, Entera announced that the Journal of Bone and Mineral Research (JBMR) published EB613 placebo controlled Phase 2 Trial results, highlighting its dual mechanism of action and rapid ...

The Linux kernel in this repository is the Linux kernel from Xilinx together with drivers & patches applied from Analog Devices. Details about the drivers that are of interest [and supported] by this ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP, will add important optionality to our clinical pipeline, as we look to develop a broad portfolio of differentiated treatment ...

Novo Nordisk and the Chinese group’s wholly-owned subsidiary The United Bio-Technology have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, ...

Analog Devices, Inc. (Nasdaq: ADI), a global semiconductor leader celebrating its 60 th anniversary, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Vincent Roche, Chief ...